Page 1 of 16

Form PTC	-144	9							at of Comme demark Off		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial N Not Yet	_
•		IN	FO						OSURE CI		Applicant	s: Alexander Ga	d and Do	ra Lis
				(Us	se se	ever	al sl	ieet	s if necessar	y)	Filing Date Herewith	s. Mexander Ge	Group A	
									U.S. PA	TENT DOCUMENTS				
Examiner Initial		Do	cun	nent	Nu	mbe	er		Date	Name	Class	Subclass	Filing I	
***************************************		3	8	4	9	5	5	0	11/19/74	Teitelbaum, et al.	-			
		3	9	9	1	2	1	0	11/09/76	Shea				
		4	3	3	9	4	3	1	7/13/82	Gaffar				
		5	2	0	4	0	9	9	4/20/93	Barbier, et al.				
		5	5	5	4	3	7	2	9/10/96	Hunter et al.				
		5	5	8	3	0	3	l	12/10/96	Stern				
		5	5	9	1	6	2	9_	1/7/97	Rodriguez, et al.				
		5	6	2	3	0	5	2	4/22/97	McLean et al.				
		5	6	2	7	2	0	6	5/6/97	Hupe, et al.			<u> </u>	
		5	6	6	8	1	1	7	9/16/97	Shapiro, et al.				
		5	7	1	9	2	9	6	2/17/98	Acton, et al.				
									FOREIGN	PATENT DOCUMENT	ΓS			
		Do	cun	nent	Nu	mb	er	_	Date	Country	Class	Subclass	Transl Yes	ation No
	wo	8		<u></u>	h	Τ,	12	9	12/29/88	US		·.	165	110
	wo wo		2	0	2	5	3 4	3	2/20/92	Europe			<del> </del>	
	wo	-	4	0	3	4	8	4	2/17/94	US	•			
· · · · · · · · · · · · · · · · · · ·		9	4	2	6	7	7	4	11/24/94	US				
		9	5	+	+	9	8	0	10/12/95	US			<del>                                     </del>	ļ
		<u> </u>	₽	2	6	╀	+	-	<del>                                     </del>					
	wo	9	5	3	. 1	9	9	J <sup>7</sup>	11/30/95	US			ــــــــــــــــــــــــــــــــــــــ	
		1								ing Author, Title, Date,				
										Polypeptide (COP-1) on ", <u>J. Neurol. Sci.</u> , 1977, <u>2</u>		h Multiple Scle	rosis and	with
		Spi	nal		d H					mas and Interleukin-2-De ate Experimental Allergio				
										ism and Specificity of th Immunol. Letters, 1997,		ne Synthetic Rar	ıdom Cop	olyme
		An	<u>n. N</u>	leur	<u>ol.,</u>	197	9, <u>6</u> ,	469	-473	reatment of Experimenta				
		Arr Cro	on, oss l	et a Reac	l., "S	Supp wit	oress h Ba	ion isic	of Experime Encephalito	ntal Allergic Encephalom gen", <u>Israel J. Med. Sci.,</u>	yelitis by a Sy 1972, <u>8</u> , 175	nthetic Copolyn 9-1760;	ner Immu	nologic
EXAMINI	CR						DA	TE	CONSIDER	ED				
										n is in conformance with MP		ine through citation	n if not in	·

Page 2 of 16

												Р	age 2 of 1	6
Form PTO	)-144 				Pate	ent a	and	Tra	nt of Comme ndemark Off	ice	Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial N Not Yet	-
		IN	FO						OSURE CI		Applicant	s: Alexander Ga	d and Do	га Lis
				(Us	se se	ver	al sł	ieet	s if necessar	y)	Filing Date Herewith		Group A	
									U.S. PAT	TENT DOCUMENTS				
Examiner Initial		Do	cun	ient	Nu	mbe	r		Date	Name	Class	Subclass	Filing D	
		5	7	3	4	0	2	3	3/31/98	Bishwajit et al.				
		5 ·	8	0	0	8	0	8	9/1/98	Konfino, et al.				
		5	8	5	8	9	6	4	1/12/99	Aharoni, et al.				
		5	8	8	6	1	5	6	3/23/99	McLean et al.				
		5	9	5	8	9	7	2	9/28/99	Hupe, et al.				
		5	9	8	Ĭ	5	8	9	11/9/99	Konfino, et al.	<u> </u>	1		
		6	0	4	8	8	9	8	4/11/00	Konfino, et al.				
		6	0	5	4	4	3	ō	4/25/00	Konfino, et al.				
		6	2	1	4	7	9	1	4/10/01	Arnon, et al.				
		6_	3	4	2	4	7	6	1/29/02	Konfino, et al.				
	<u> </u>	6	3	6	2	1	6	1	3/26/02	Konfino, et al.		1	1	
									FOREIGN	PATENT DOCUMENT	S			
		Do	cun	nent	Nu	mbe	er		Date	Country	Class	Subclass	Transl: Yes	ation No
	wo	9	5	3	$\overline{\int_{1}}$	9	9	0	11/30/95	US				
	wo	1	5	3	3	4	7	5	12/14/95	Europe				
	wo	9	8	3	0	2	2	7	7/16/98	us				
	wo	0	0	0	5	2	4	9	2/3/00	US				
	wo	0	0	0	5	2	5	0	2/3/00	US				
	wo	o	0	l	8	7	9	4	4/6/00	US				<u> </u>
			o	ТН	ER	DO	CUI	ИE	NTS (Includ	ing Author, Title, Date,	Pertinent I	Pages, Etc.)		
				, et a Abstr			pres	sioi	of EAE in E	Baboons by a Synthetic Po	olymer of A	mino Acids", <u>N</u> e	<u>eurol.</u> , 19'	78, <u>28</u> ,
		The	e Su	ippr	essio	on o	ensit	izat peri	tion of Experi mental Allerg	mental Allergic Encephal	omyelitis wi Multiple Scl	th Synthetic Pep erosis (Academic	tide Analo Press, Ne	gues" ew Yor
	_	Arı	non,		Syn	thet				ino Acids in a Clinical Tr			gress in M	lultiple
		Scl	eros	sis F	Rese	arch	(Ba	uer	, Ritter, eds.,	Springer Verlag New Yo	rk, 1980) 4	16-418;		
				, "E: <u>55</u> , :	-		ntal	Alle	ergic Encepha	alomyelitis - Susceptibilit	y and Suppi	ession", <u>Immun</u>	ological I	Rev.,
		Arı Ap	non, pro:	, et a	al., ' to M	'Sup 1yel	pres in D	sioi isea	n of Demyelin se (G. Serlup	nating Diseases by Synthe	tic Copolyr Publishing (	ners", in <u>A Mult</u> Corp., 1988) 24	idisciplin 3-250	ary
EXAMINI	ER						DA	TE	CONSIDER	ED				
										n is in conformance with MPE		line through citation	n if not in	

Page 3 of 16

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office JPW/ GJG/DJK INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith U.S. PATENT DOCUMENTS Filing Date Class Subclass Document Number Date Name Examiner if Appropriate Initial 2/4/03 Gad et al. 9/16/03 Ю 8 Konfino, et al. 20 01 00 55 56 8 A1 12/27/01 Gilbert, et al. 20 02 00 37 84 8 03/28/02 Eisenbach-Schwartz et al. A1 |20 |02 |01 |07 |38 |8 08/08/02 Vandenbark A1 20 02 01 15 10 3 Gad, et al. A1 8/22/02 20 03 00 04 09 9 A1 01/02/03 Eisenbach-Schwartz et al. 7/22/99 09 3 Strominger, et al. 5 9 10 7 7 09 8 1/20/00 7/20/02 09 09 FOREIGN PATENT DOCUMENTS Translation Document Number Country Class Subclass Date Yes No 4/13/00 wo lo US US wo 5/18/00 wo ю 7/26/01 US US WO 8/23/01 10 Ю 13 [9 8 12/3/01 US wo Ю 3 wo lus 2 12/13/01 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Pending claims of U.S. Serial No. 09/816,989 (Gad et al.)(Item 28)., U.S. Patent Publication No. 20020115103 A1, for the Examiner's convenience Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689; Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", Israel J. Med. Sci., 1993, 29, Arnon, et al., "On the Existence of Suppressor Cells", Int. Arch. Allergy Immunol., 1993, 100, 2-7; Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", Therapeutic <u>Immunol.</u>, 1994, <u>1</u>, 65-70; DATE CONSIDERED EXAMINER \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Page 4 of 16 Serial No. Atty. Docket No. Form PTO-1449 **U.S. Department of Commerce** 60807-AA-PCT-US/ Not Yet Known **Patent and Trademark Office** JPW/ GJG/DJK INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith **U.S. PATENT DOCUMENTS** Filing Date Class Subclass Examiner Document Number Date Name if Appropriate Initial 09 09 8 9 6/5/01 Yong and Chabot 09 8 6/5/01 Rodriguez and Ure FOREIGN PATENT DOCUMENTS Translation Document Number Date Country Class Subclass Yes US wo 6 12/27/01 2 EΡ 03 8 0 A2 8/22/90 Europe EΡ 03 5 B1 11/29/95 Еигоре OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Babu et al., "Reevaluation of response patterns of nonresponder mice to GLPhe polymers", Immunogen., 1983, 18(1): 97-100 (Abstract) Babu et al., "Ir gene control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", J. Immunogenet., 1984, 11(3-4): 251-254 Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", Seminars in Neurol., June 1994, 14(2), 146-Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", Neurol., 1988, 38(Suppl. 2), Baxevanis et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu<sup>40</sup>Ala<sup>60</sup>) and Poly (Glu<sup>51</sup>Lys<sup>34</sup>Tyr<sup>15</sup>): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies",

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Immunogenetics, 1980, 11: 617-628

DATE CONSIDERED

EXAMINER

Page 5 of 16

Form PTO-1	1449						nt of Commendemark Offi		Atty. Doc 60807-AA JPW/ GJG	-PCT-US/	Serial N Not Yet		
	INF						OSURE CIT		Applicants	: Alexander G	ad and Do	ora Lis	
		, ( <b>c</b>	Jse se	eve	erai sii	eeu	s if necessary	· · · · · · · · · · · · · · · · · · ·	Filing Date Herewith		Group A	rt Unit	
					_		U.S. PAT	TENT DOCUMENTS					
Examiner Initial	Docu	ımen	t Nu	ıml	ber		Date	Name	Class	Subclass	Filing I	Date opriate	
		+	+	╀		_							
						<u> </u>	EODEICN I	A TENT DOCUMENTS	<u>. l</u>				
								PATENT DOCUMENTS		G 1 1	Transl	ation	
	Doci	ımen	it Nu	ım	ber		Date	Country	Class	Subclass	Yes	No	
	$\dashv$	Т	$\top$	Т	Т	Г	<del> </del>				1	1	
		+	+-	+		-				<del> </del>	╁	<del> </del>	
				丄		<u> </u>		<u> </u>	<u> </u>	L	<u> </u>	<u> </u>	
		OTI	<u>IER</u>	De	OCUN	1E	NTS (Includi	ng Author, Title, Date, l	Pertinent P	ages, Etc.)			
	Ben-Nun, et al., "The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (M Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease", <u>J. N</u> 243(Suppl. 1), S14-S22  Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminar												
	Borr	stein	, et a	c Polypepti	de: Preliminary	Results"	, <u>Ann.</u>						
							nt of Multiple , 348-350;	Sclerosis with a Synthetic	Polypeptide	:: Preliminary Ro	esults", <u>Tr</u>	ans. Am	
	Borr	stein	, et a	al.,	"Mult	iple	Sclerosis: Tr	rial of a Synthetic Polyper	otide", <u>Ann</u>	Neurol., 1982,	<u>11</u> , 317-	319;	
	1983	, <u>42</u> ,	356	(A	bstrac	t)		nal Human Lymphocytes to					
	Воп 366-	stein 372	ı, et a	al.,	"Clini	cal		oolymer 1 in Multiple Scle					
	Scle	rosis'	" in C	Goi		t al.		enthetic Polypeptide (Copical and Clinical Aspects					
	1985	i, <u>35</u>	(Sup	pl.	1), 10	3 (	Abstract)	linical Trials of a Syntheti					
	Adv	The	r. (U	SA	<u>()</u> , 198	7, <u>4</u>	<u>4,</u> 206 (Abstra	or Patients with Exacerbat act)					
	1987	7, <u>317</u>	<u>7</u> (7),	40	8-414			l in Exacerbating-remittin					
							-	vith COP-1 in Multiple Sc					
	The	Inter	natio	na	in Chronic Progressive M inference: An Update on M her, 1989, 225-232	ultiple Scle <u>Aultiple Scl</u>	rosis: Prelimina erosis, Roma (I	taly), Sep	t", from stember				
EXAMINER		,					CONSIDERI					•	
*EXAMINER conformance as	: Initial if	citatio sidere	on con	nsid lud	ered, w	heth of th	er or not citation is form with ne	n is in conformance with MPE xt communication to applicant	P 609: Draw l	ine through citation	n if not in		

Page 6 of 16

Form PTO-1	449						nt of Comme ademark Off		Atty. Doc 60807-AA JPW/ GJC	\-PCT-US/	Serial N Not Yet	i Known
	INI						LOSURE CIT		Applicant	s: Alexander G	ad and Do	ora Lis
		,,	JSC S	ev	CI 31	onee	is ii necessary		Filing Date Herewith		Group A	rt Unit
					·		U.S. PAT	TENT DOCUMENTS				
Examiner Initial	Doc	umer	nt Nu	ım	ber		Date	Name	Class	Subclass	Filing I	Date opriate
<u> </u>	_		_	4	-	-				<del>                                     </del>	<b> </b>	
										<u> 1</u>	_L	
	-T			_	-		T	PATENT DOCUMENT			Transl	ation
	Doc	eumer	it Nu	ım	iber		Date .	Country	Class	Subclass	Yes	No
			Т	Т	_						165	110
	-		+	+	+	+	<del> </del>		<del> </del>	<del> </del>		
										<u> </u>	_l	L
	1_							ing Author, Title, Date,			1	0.0
							Trials of Cop 1990) 469-48	o 1 in Multiple Sclerosis" 30	in <u>Handboo</u>	ok of Multiple S	clerosis (	S.D.
								, Double-blind, Randomi ', <u>Neurol.</u> , 1991, <u>41</u> , 533		nter, Pilot Trial	of Cop 1	in
	Des							Sclerosis with Copolymos (Rudick R.A. & Goodki				
	Bro			., '	"Сор	olym	er 1: Effect or	n Normal Human Lympho	ocytes", An	n. N.Y. Acad. S	ci. (USA)	, 1984,
	<u>35</u> ,	1754	-1759	9				ls of Copolymer 1 in Nor			•	
	Neı	ırol.,	1985	<u>, 3</u>	<u>5</u> (St	ıppl.	1), 170 (Abst					
	<u>36,</u>	92-94	1					Response to Copolymer				
	Net	<u>ırol.,</u>	1991	۱, ہ	<u>41, 1</u> :	317-	1319	o Inhibit the Human T-ce				
								or Multiple Sclerosis", <u>Dr</u>				
	The Trie	erapy	of M taly:	uli	Sclerosis. The Present an ase Medline on STN, Inst 5, Recent Progressi in Mo	ituto do Cli	nica Neurologic	a, Univer	sit`a,			
	Clir 199	nical 1	Γrial					Pharmaceutical Industrie				
		nical olled					o. 9002, Lemn	non Co. and Teva Pharma	aceutical Inc	lustries, Ltd., fir	rst patient	: 
EXAMINER					D	ATE	CONSIDERI	<b>ED</b>	•	•		
*EXAMINER conformance ar	Initial i	f citation	on cor	nsio	dered, de cop	wheth	her or not citation	n is in conformance with MPE xt communication to applican	EP 609: Draw	line through citation	n if not in	

Page 7 of 16

Form PTO-	1449							nt of Commender demark Offi		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial N Not Yet	
	IN	FOI						OSURE CIT		Applicant	s: Alexander G	ad and Do	ra Lis
			(Us	e se	ver	ai sn	ieet	s if necessary	y) 	Filing Date Herewith		Group A	rt Unit
								U.S. PAT	TENT DOCUMENTS				
Examiner Initial	Do	cum	ent	Nur	nbe	er	1	Date	Name	Class	Subclass	Filing I	
	+-	╁	-		-	╫	-	<del> </del>		1		<del>-</del>	
1					<u> </u>		1	FOREIGN I	PATENT DOCUMENTS	_ <del>'</del>	<u> </u>		
	Do		ient	Ni		~=		Date	Country	Class	Subclass	Transl	ation
	Do	cum	lem	Mui	IIDI	er.		Date	Country	Class	Subciass	Yes	No
				·									
		╁╴				T			<u> </u>				
	·	Щ.		<u> </u>	L_			L		<u>l</u>			
	IC.	ban.	THE	ER I	DO	CUN	ME.	NTS (Includi	ing Author, Title, Date, Instemic Autoimmunity, 4th	ertinent I	ages, Etc.)		
	Co	nen,	, ru	mua	mei	iiiai i	11111	iunology , <u>ay</u>	sterne Autominiumty, 4	Lu., 1999,	1003		
	T.	- 00	3D 1	14.	14: -		- C	liniaal and Da	search Group Study, "CO	D 1 Multio	anter Triel in D	alancina	
	Re	e CC mitti	JP-1 ing N	Mult	intic	ente: e Scl	r Ci ero:	ollow Up", Abstracts of Sy	mposia and	d Free Commun	ication,		
	Ba	rcelo	ona (	(Spa	in),	, Jun	e 25	5-29, 1994, <u>2</u> 4	41 (Suppl. 1), 6				
	Co 13		, "O <sub>I</sub>	ption	ns f	or M	lulti	ple Sclerosis	Therapy", J.A.M.A. Medi	<u>cal News &amp;</u>	& Perspectives,	1994, <u>272</u>	<u>2</u> (18),
	De (T	eb e G)-A	t al., AL in	"Co rab	omp	paris s", <u>J.</u>	ion Im	of Freund's a munol. Metho	and Ribi adjuvants for induods, 1992, 152(1): 105-11	cing antibo	odies to the syn	thetic anti	gen
	De	Kru	ıyff	et al	., "	Anal	ysis	of T Cell Re	sponses to Poly-L (GluLy	s) at the Cl	onal Level. I. P	resence o	f
	Re	spor	nsive	Clo	one	s in I	Von	responder Mi	ice", Eur. J. Immunol., 198	37, 17 (8):	1115-1120 (Ab	stract)	
1									ting", <u>Curr. Opinions Imm</u> ple Sclerosis", <u>Instituto di</u>			Sictema	Nervosc
						no, 4			pie scierosis , <u>mistituto di</u>	Cinica de	rie ivialattie de	Disterna	rervose
	Fa	lo et	al.,	"An	aly	sis o	f an	tigen present	ation by metabolically ina	ctive acces	sory cells and th	neir isolat	ed
<u> </u>									A, 1985, 82(19): 6647-665				
									ase", New Eng. J. Med., 1 ple Sclerosis", J. Clin. Pha			1003 18	77-84
Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Antigens from the MHC Class II Binding Site", Department of Chemical Implication of Science, 1994												Weizman	<u>in</u>
	Fr Hi	idkis stoc	s-Hai	reli, atibi	et a	al., " Cor	Dir mpl		f Myelin Basic Protein and on Living Antigen-Presen 1872-4876				
EXAMINER DATE CONSIDERED													
*EXAMINER conformance a	R: Initial nd not c	if cita	ation lered.	cons	ider ude	red, w	heth of th	er or not citation	n is in conformance with MPEI xt communication to applicant.	2 609: Draw	line through citation	n if not in	

Page 8 of 16

Form PTO-14	149					of Comme emark Off		Atty. Doc 60807-AA JPW/ GJC	A-PCT-US/	Serial N Not Ye	ło. t Known		
	INFO					SURE CIT		Applicant	s: Alexander Ga	d and Do	ora Lis		
		(US	e sev 	erai sh	eets 1	f necessary	y)	Filing Date Herewith		Group A	rt Unit		
						U.S. PAT	TENT DOCUMENTS		-				
Examiner Initial	Docum	nent	Nun	Class	Subclass	Filing I	Date opriate						
		-								<del> </del>			
			Ш			OBBIGNI	DATE DO CURATION			<u> </u>			
					F		PATENT DOCUMEN			Transl	ation		
	Docun	nent	Nun	nber		Date	Country	Class	Subclass	Yes	No		
		Т	П		$\vdash$			<u> </u>		1 23	1.0		
		+	$\vdash$	+	$\vdash$								
		<u> </u>					<u> </u>			<u> </u>	<u> </u>		
							ing Author, Title, Date						
								lymer 1 to Class					
	21-22				npiex	Molecules	on Living Antigen Pres	enting Cetts	, israeli biochen	<u>n. 30c.</u> , 1	994,		
					Synthe	ng of MBP, I	PLP and MOG P	eptides to	o Class				
				ompatil	esenting Cell	s" in <u>Neurochem</u>	<u>1 Mtg.,</u> A	ugust					
				1 66	· · · · · · · ·	1 I-bibia aba Diadi	of MDD I	DI D and MOC D	antidos to	Class I			
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOC II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Neuroch 14-19, 1994  Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOC Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", J. Neurochen 561  Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require P												
		-Hai	reli, o	Protein do 1	not Require Proc	essing Pr	ior to						
	Bindin	g to	Clas	s II Ma	jor Hi	stocompati	bility Complex Molecu	les on Living	Antigen Presen	ting Cell	s",		
	Depart	men	t of (	Chemic:	al Imr	nunology, '	The Weizmann Institute mer I and Myelin Basic	of Science,	Rehovot, Israel,	1994	Prior to		
							patibility Complex Mol						
	Immur	iol. S	Soc.,	May 3-	4, 199	94 (Abstrac	et)						
							mer 1 and Myelin Basic						
1				s II Ma 5, <u>163</u> , 2			ibility Complex Molecu	les on Living	Antigen-Presen	ing Cells	s', <u>Cell.</u>		
	Fridkis	s-Ha	reli,	et al., "] 8, <u>160,</u> 4	Promi	scuous Bin	ding of Synthetic Copo	lymer 1 to Pu	rified HLA-DR	Molecule	es", <u>J.</u>		
	Fridkis	s-Ha	reli,	et al., "	Synth	etic Amino	Acid Copolymers that le. Natl. Acad. Sci., 1998			Inhibit	Type II		
							m copolymers of three a			nolecules	", <u>Intl.</u>		
	Immur	<u>10l</u> .,	1999	, 11(5)	: 635-	641							
	Fridkis	s-Ha	reli e	t al., "S	ynthe	tic Peptide	s that Inhibit Binding of	f the Collage	n Type II 261-27	3 Epitop	e to		
	Rheum	nator	d Ari I⊂∧i	thritis-A	ASSOCI n STN	ated HLA-	DR1 and DR4 Moleculent of Clinical Immuno	es and Collag	gen-Specific 1-ce	ital. Aarl	nses , hus		
1	Denma	ark,	HCA	APLUS	AN: 2	2000:45505	33, Human Immunology	, 2000, <u>61</u> (7	): 640-650 (Abs	tract)	,		
	Grgaci	ic, et	al., '	"Cell-m	ediate	ed Immune	Response to Copolyme ay", Int. Immunol., 199	r 1 in Multip	le Sclerosis Mea		the		
	Gurevi	ich, '	'Stuc	ly of th ci., 199	е МН	C-competit	ion Between BP and Co	op 1 Using H	uman Cytotoxic	T-cell Cl	ones",		
EXAMINER						ONSIDER	ED						
*EXAMINER	Initial if cit	ation	consi	dered. w	hether	or not citatio	n is in conformance with MI	PEP 609: Draw	line through citation	n if not in			
conformance and	d not consid	lered.	Inclu	de copy	of this	form with ne	xt communication to applica	int.					

Form PTO-1	449					nt of Comme ademark Off		Atty. Doc 60807-A/ JPW/ GJO	A-PCT-US/	Serial N Not Yet	
	· INF					LOSURE CI' ts if necessar		Applican	s: Alexander G	ad and Do	ora Lis
								Filing Date Herewith		Group A	rt Unit
						U.S. PA	TENT DOCUMENTS				
Examiner Initial	Docu	ment	Nui	mber		Date	Name	Class	Subclass	Filing I	
	++		$\vdash$	$\vdash$	+-						
	<u> </u>		•	<u> </u>		FOREIGN	PATENT DOCUMENT	S			
	Doci	ıment	Nin	mher		Date	Country	Class	Subclass	Transl	ation
	Doce	minem		IIIJCI		Date	Country		- Substant	Yes	No
		—— ОТН	ER I	DOC	UMF	NTS (Includ	ling Author, Title, Date,	Pertinent 1	Pages, Etc.)		
	Harr		nd H	afler	Therapy for Autoimmune			mmunol.,	2000,		
	Henr	y, Cel	lia M	t. 18, 2000	49-54						
						f immune resp 95: 329-331 (	ponse gene control for indu Abstract)	iction of epi	tope-specific sup	pression b	y TGA
	Jaco	bs, et	al., "	Adva	nces	in Specific Tl	herapy for Multiple Sclero	osis", <u>Neuro</u>	<u>1.</u> , 1994, <u>7</u> , 250	-254	_
		gress f					er 1 Therapy for Exacerba anding and Treatment of M				
	Neur	ol., 19	994,	36(S	uppl.	), 115-117	lapsing-Remitting Multip				
	Abst	racts,	1996	5, <u>12:</u>	5, 291	993b	mitting Multiple Sclerosis				<u>emical</u>
	tyros	ine 10 aining	(GA	AT). I amic	V. In acid	duction of CC and tyrosine",	ies against the terpolymer GAT idiotype following in , <u>Eur. J. Immunol</u> ., 1979,	munization 9(7): 553-5	with various sy (Abstract)	nthetic po	
	Kay, 99	et al.	, "Tł	ne Me	chan	ism of Action	of FK 506", Transplantat	ion Proceed	<u>lings</u> , 1990, <u>22</u> (		
	Ence	phalo	mye	litis i	n Gui	nea Pigs" <u>J. N</u>	Synthetic Polypeptide, on ( Neurol. Sci., 1979, <u>42</u> , 267	-274 .			
							sease in Bone Marrow Tra Years", Int. Arch. Allergy				ory, an
	Keps on S	sutlu e TN, E	t al., Pepai	, "Eva	aluati it of F	on of Chitosa harmaceutica	n Used as an Excipient in il Technology, Gulhane M I, Acta. Pol. Pharm. 1999,	Tablet Form	nulations", Data ical Academy, A	abase HC	APLUS 6018,
EXAMINER		,	14			CONSIDER			, , , , , , , , , , , , , , , , , , , ,		•

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 10 of 16

Form PTO	-1449						nt of Comme ademark Off		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial N Not Yet			
	]	NFO					LOSURE CI		Applicant	s: Alexander Ga	d and Do	ora Lis		
			(Us	se se	veral s	hee	ts if necessar	y)	Filing Date Herewith	3. Mexander Ga	Group A			
					_		U.S. PAT	TENT DOCUMENTS						
Examiner Initial		Oocun	nent	Nur	mber		Date	Name	Class	Subclass	Filing I			
		·	_	L_		$\bot$					<u> </u>			
							1	<u> </u>			<u> </u>			
							FOREIGN !	PATENT DOCUMENT	<u>S</u>		Teri v			
	J	Docun	nent	Nui	mber		Date	Country	Class	Subclass	Transl	T		
							ļ				Yes	No		
									<u> </u>					
			TU	rd i	DOCI	NATE	NTS (Includi	ing Author, Title, Date,	Partinant I	Pages Etc.)		•		
		Kott, e	t al.,	, "C	OP-1 I	ncre	ases Suppress	or Cells Number in Multi			logical A	ssoc.,		
		Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Advisor 19-20</u> , 1994, Herzliya (Israel), 17  Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues NNH <sub>2</sub> -Terminal Including Proline as a Stop Signal for Trimming", <u>J. Immunol.</u> , 1993, 151: 4732-4742  Lai et al., "Complementation of Class II A alleles in the immune response to (GluLysTyr) polymers", <u>I</u>												
							on of Class II : 38-48 (Abst		esponse to (	GluLysTyr) poly	/mers", <u>E</u>	xp. Clin		
								s to two epitopes on a sing 99-3804 (Abstract)	gle immuno	gen controlled b	y two dis	tinct		
	1	<u>[mmur</u>	<u>10l.,</u>	1979	9, <u>123</u> ,	215	6-2160 (Abst	nide on Suppressor Cell A						
	1	srael.	J. M	ed. S	<u>Sci.,</u> 19	79,	<u>15,</u> 868-869 (	ncephalomyelitis in Mice Abstract)						
							rotein Drug D )) 691-695	Delivery" in Advances in I	Parenteral S	ciences (Vincen	t H.L. Le	e, ea.,		
			l., "C	Glati				activation of THP-1 cells	by interfer	on-γ", <u>Eur. J. Ph</u>	armacol.	, 1998,		
		Experi	imen	tal A	Allergio	En <sub>2</sub>	cephalomyelit	Copolymer 1 (Cop-1) on its (EAE)", <u>J. Neurol. Sci</u>	<u>,</u> 1983, <u>62,</u>	281-293		ons of		
	l,	polym	ers",	Yol	koham	<u>a M</u>	ed. Bull., 198	Class II A alleles in the i 8, 39(1-2): 9-19 (Abstract	)					
		and th	e ter	poly	Interpr mers p 44-356	oly	(Glu55Lys37I	ne responses of mice to po Leu8) and poly (Glu56Ly	oly(Glu60L; s37Ser7)", <u>(</u>	ys40), its modifi Clin. lmmunol. l	ed deriva mmunop	itives, athol.,		
		McDe	rmot	t, et	al., "A 980, <u>40</u>	ntig	en-induced Si	appression of Experiment	al Allergic	Neuritis in the G	uinea Pig	g", <u>J.</u>		
EXAMINE	R	-			DA	ATE	CONSIDER	ED						

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-14	149					ent of Comme rademark Off		Atty. Doc 60807-AA JPW/ GJO	A-PCT-US/	Serial N Not Yet	
	INF					LOSURE CI		Applicant	s: Alexander G	ad and Do	ora Lis
		(U	se se	vera	il she	ets if necessar	y) 	Filing Date Herewith		Group A	rt Unit
						U.S. PA	TENT DOCUMENTS			_	
Examiner Initial	Docu	ımen	t Nu	mbei	r	Date	Name	Class	Subclass	Filing I	
	++		+	$\vdash$					+		
						FOREICNI	DATENT DOCUMENT	<del></del>	<del>-</del>	<del></del>	
							PATENT DOCUMENT			Transl	ation
	Docu	ımen	t Nu	mbe	r	Date	Country	Class	Subclass	Yes	No
	+	Т	Т-	П					-	1 65	110
			+	Н					<del></del>	<u> </u>	<del> </del>
						l					<u> </u>
		отн	ER	DOC	CUM	ENTS (Includ	ing Author, Title, Date,	Pertinent l	Pages, Etc.)		
	Meir	er, "C	COP-	-1 M	ultice		rial in Exacerbating-rem			e Year Fo	ollow-
	Two	-year	Follo	ow-u	p", in	9th Congress of	ticenter Clinical Trial in lof the European Committ vember, 1993, 48 (Abstr	ee for Treati			
	Men	gle-G	aw, '	The	Majo 602-	r Histocompat	ibility Complex (MHC)"	, in <u>Encycl.</u>	Molecular Bio. (	Oxford B	lackwe
					tion c		c Protein-specific Human	T-cell Line	s by COP-1", <u>ls</u>	rael J. Me	d. Sci.,
	I Mo	nocy	te-M	lacro	phage	-1 (COP-1) Re e Cell Line" in stract)	gulates Class II MHC Ex The IBC Conference on	pression and Multiple Sc	i Cytokine Synt lerosis, San Die	hesis in th	ne THP-
<del> </del>							1 and IFN-Beta on Immu	ne Response	s to Myelin Bas	ic Proteir	ı",
	Neur	<u>ol.</u> , 1	994,	44(5	Suppl	. 2), A212					
	Prote	ein", <u>,</u>	Assa	f Har	rofeh	ffect of Copoly Medical Center 4, 22	mer-1 and Interferon-β or, Sackler School of Med	on the Immu licine, Tel-A	ne Response to viv University	Myelin B of Maryla	asic <u>nd</u>
	Milo Prote	, et al	l., "C / Inhi	opol ibitin	lymer ig An	-1 and Interfer tigen Presentat	on-β Additively Suppression", <u>J. Neuroimmunol.</u> ,	1994, <u>54</u> , 18	33 (Abstract)		
	Prote	ein", .	J. Ne	uroii	mmur	<u>101.,</u> 1995, <u>61,</u>					
	1990	), <u>8</u> (1)	), 119	9-14	1		s of Therapeutic Trials fo				
	<u>50</u> (4	), 845	5-847	7		_	ational Drugs for Treatme				
EXAMINER	lo,c	onnor	et a			ers" in The Sci	ence and Practice of Pha	rmacy, Rem	ington, 1995, <u>2,</u>	1398-16	
	·										
							on is in conformance with MP ext communication to applicat		line through citatio	n if not in	

Page 12 of 16

FOREIGN PATENT DOCUMENTS    Document Number   Date   Country   Class   Subclass   Translation   Yes   No											
(Use several sheets if necessary)    Spinature   Country   Class   Subclass   Filing Date   Filing Date   Foreign PATENT DOCUMENTS	Form PTO-	1449						60807-A	A-PCT-US/		
U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  Examiner Initial  Document Number  Date  Name  Class  Subclass  Filing Date   Ir Appropriate  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  Document Number  Date  Country  Class  Subclass  Filing Date   Ir Appropriate  FOREIGN PATENT DOCUMENTS  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 45: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", **Limmunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", **L. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", *Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 2, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", *Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Thibition of Allorecognition and Prevention of Graft-Versus 10 of Allorecognition of Graft-Versus 10 of Allor		IN						Applicant	s: Alexander G	ad and Do	ra Lis
Document Number   Date   Name   Class   Subclass   Filing Date   if Appropriate			(U	se se	veral sh	eets if necessary	·	Filing Date			
FOREIGN PATENT DOCUMENTS   Document Number   Date   Country   Class   Subclass   Translation   Yes   No						U.S. PAT	ENT DOCUMENTS				
Document Number   Date   Country   Class   Subclass   Translation   Yes   No	Examiner Initial	Do	cumen	t Nur	nber	Date	Name	Class	Subclass		
Document Number   Date   Country   Class   Subclass   Translation   Yes   No			<del>                                     </del>	$\bot$					1		
Document Number   Date   Country   Class   Subclass   Translation   Yes   No			<u> </u>		<u> </u>	L			<u> </u>	.1	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Thereution of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Thereution of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu5Tty-38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)						FOREIGN F	Ī		<del></del>	Transl	ation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Ir, W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", L. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Do	cumen	t Nur	nber	Date	Country	Class	Subclass		
Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood. 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  DATE CONSIDERED				T	· · ·			-		Yes	NO
Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class Il Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class Il Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  DATE CONSIDERED								-	-	-	
Pender, et al., Internal Med. Journal, 2002, 32: 554-563  Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood. 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  DATE CONSIDERED					l . l						
Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659  Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-Versus Graft-Versus Host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  DATE CONSIDERED			ОТН	ER I	DOCUN	AENTS (Includi	ng Author, Title, Date,	Pertinent I	Pages, Etc.)		
Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2. 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)		Per	ider, et	al., I	nternal l	Med. Journal, 20	02, 32: 554-563				
Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2. 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)											
Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann Neurol., 1999, 46: 253-256  Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-1 Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 2, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Por	ter, "C	oatin	g of Pha	rmaceutical Dosa	age Forms," in The Scier	ce and Prac	tice of Pharmac	y, Remin	gton,
Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476  Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 2, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		199	95, <u>2</u> , 1	650-l	1659						
Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 2, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in							Multiple Sclerosis: Relat	tion with Di	sease Course ar	d Therap	y," <u>Ann</u>
Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84  Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Pur	i et al.,	"Mo	dulation	of the Immune I	Response in Multiple Scl	erosis", <u>J. I</u>	mmunol., 1997,	<u>158,</u> 247	1-2476
Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416  Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396  Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37 <sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in								fic T Cell A	ctivation: Interf	erence wi	th
Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565  Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Rei 138	lly, Jr., 30-1416	, W.J.	., "Phari	maceutical Neces	sities" in The Science an				
1991, 9, 527-565		Ro	lak, "C	opoly	mer-I T	herapy for Multi	ple Sclerosis", <u>Clin. Neu</u>	ropharmacc	logy, 1987, <u>10</u> (	5), 389-39	96
Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)  Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37 <sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		199	1, <u>9</u> , 5	27-5 <del>(</del>	65						
Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in										<u>Departme</u> i	<u>nt of</u>
Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810  Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	<del> </del>	_								1aior	
Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37 <sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in									ing to Class II w	Tajoi	
Hematology, 37 <sup>th</sup> Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)  Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Scl	ilegel,	et al.,	"Inhibi	tion of Allorecog	nition and Prevention of	Graft-vs-ho			
Schwartz et al., "Gene complementation in the T lymphocyte proliferative response to poly (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in											n. Soc.
(Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract)  EXAMINER  DATE CONSIDERED  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in										(1)	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		(GI	u57Ly	s38T	yr5): Ev					ļ., 1979, l	23(1):
	EXAMINE					TE CONSIDERE	ED				
	+FW 4 P 475 172 27				1		io in nonformation with MDF	D 600, D	ling through site!	n if not in	
									mie unough chano	11 1101 111	

Page 13 of 16

Form PTO-	1449	)						t of Commer demark Offi		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial N Not Yet	
		INFO						OSURE CIT s if necessary		Applicants Filing Date Herewith	s: Alexander Ga	Group A	
								U.S. PAT	ENT DOCUMENTS		·	<u> </u>	
Examiner Initial		Docum	nent	Nur	nbe	r		Date	Name	Class	Subclass	Filing I	
	-	-	├	├	_							<del>                                     </del>	
I	1		L	<b>!</b>	l.—	_		FOREIGN F	PATENT DOCUMENTS	<u>-</u>			
		Docum	ent	Nur	mbe	r		Date	Country	Class	Subclass	Transl	ation
									,			Yes	No
			_										
										<u> </u>			
		o	TH	ER I	DOC	CUN	1E	NTS (Includi	ng Author, Title, Date, l	Pertinent P	ages, Etc.)		
		Sela, e Sympo Basel,	siun	n of	Org	mer an S	ital pec	ephalomyelitis" in <u>Menari</u> uunity", Cremona, Italy, Ju	ni Series or ine, 1977, (	<u>Immunopatho</u> Miescher P.A. o	logy, vol. ed., Schw	1, First abe Co.,	
			t al.,	"Su	ppre		PP-1 in EAE and its Relev	ance to Mu	Itiple Sclerosis'	', <u>Bull. In</u>	st.		
								s Immunomo 0/71, 147-15	odulatory Vaccines Agai 5	nst Multipl	e Sclerosis", N	<u>//akromol</u>	. Chem
		Starzl,	Trai	nspla	anta	tion	Pro	ceedings, 199	90, <u>22</u> (1, Suppl. 1), 5				
									atments for Multiple Sclen			COP-1) T	reatmen
		Investi	gatio	onal	Nev	v Di	ug (	(IND) Progra	m", <u>Ann. Neurol., 1994, î</u> ion", <u>Faseb J.</u> , 1996, <u>10</u> ,	<u>36, 114-115</u> 721-730	<u> </u>		
		Tarcic	et a	l., "(	Cope	olyn	ner l	(Copaxone)	from an Idea to a Drug fo N 1997:333270. Kim, Ha	or Treatmer	nt of Multiple So 1997, <u>281</u> (14),	clerosis" 16-18 (A	bstract)
		Teitelb Eur. J.	aun Imn	ı, et nunc	al., ' ol., 1	"Su <sub>l</sub> 971	opre , <u>1</u> ,	ession of Expe 242-248	erimental Allergic Encept	alomyelitis	by a Synthetic	Polypepti	ide",
		Israel .	J. M	ed. S	Sci.,	197	1, 7	, 630-631 (A		.,,,			
		1 eitelb 566	aum	ı, et	al.,	Pro	teci	tion Against i	Experimental Allergic End	epnaiomye	ntis , <u>mature,</u> i	972, <u>240</u> ,	, 304-
Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with B Immunol., 1973, 3, 273-279													
									ies on Experimental Aller 2-1173	gic Enceph	alomyelitis Sup	pression	by COP
1", Israel J. Med. Sci., 1974, 10(9), 1172-1173  EXAMINER DATE CONSIDERED													
									n is in conformance with MPE axt communication to applicant		ine through citatio	n if not in	

Page 14 of 16

Form PTO	1449	)						t of Commer demark Offi		Atty. Doc 60807-AA JPW/ GJC	A-PCT-US/	Serial N Not Yet	
		INF						OSURE CIT			s: Alexander Ga	ad and Do	ora Lis
			(U	se se	ver	rai sh	eets	s if necessary	y) 	Filing Date Herewith		Group A	
								U.S. PAT	TENT DOCUMENTS				
Examiner Initial		Docu	ımeni	t Nu	mb	er		Date	Name	Class	Subclass	Filing I	Oate opriate
				L									
ļL					L.			L <u></u>			<u> </u>		
	<del>-</del>							FOREIGN I	PATENT DOCUMENTS	<u> </u>	<del></del>	Im	
	ļ	Docu	men	t Nu	mb	er		Date	Country	Class	Subclass	Transl	
ļ		-		T .	Г	т-т						Yes	No
		$\perp$	$\bot$	$oldsymbol{oldsymbol{\perp}}$	L	1-1			`	ļ	ļ		
	l												ļ
			отн	ER	DO	CUM	1EN	NTS (Includi	ing Author, Title, Date,	Pertinent I	Pages, Etc.)		
		Teite	lbaur	n, et	al.,	, "Sup	pre	ssion of Expe	erimental Allergic Enceph unol. Immunopath., 1974	alomyelitis	in Rhesus Mon	keys by a	1
								ssion of Expe (Abstract)	erimental Allergic Enceph	alomyelitis	in Baboons by	Cop 1", <u>1</u>	srael J.
-	-	Teite	lbaun	n, et	al.	. "Blo	cki	ng of Sensiti	zation to Encephalitogen	ic Basic Pr	otein in Vitro b	y Synthe	tic Basic
		Copo 1979	olyme ) 681	r (C) -685	OP	1)" ii	n <u>C</u>	ell Biology a	and Immunology of Leuko	ocyte Funct	ion (Academic	Press, Ne	w York
		Rele	vance	to N	/ul	tiple S	Scle	rosis", in <u>Hu</u>	ntal Allergic Encephalomy moral Immunity in Neuro ing Corp., 1979) 609-613	logical Dis			nthal A.
		Teite supp	lbaur	n, et /e Co	al.,	, "Mo	noc	lonal Antiboo	dies to Myelin Basic Protect 7 <sup>th</sup> Eur. Immunol. Mtg.,	ein Cross R	eact with Synth, September 8-1	etic EAE 3, 1985	•
									of the T-cell Response to		ic Protein by the	e Synthet	ic
									<u>ci. USA, 1988, 85, 9724-</u> polymer 1 in Multiple Scl		and Mad Assa	2 1000	
			10aui <u>'I</u> (9),				nca	ii Triai oi Co	polymer i in wunupie sei	CIOSIS <u>J. 1</u>	staet Wieu. Asso	<u>c.</u> , 1909,	
		Teite	lbaur	n, et	al.,	, "Cro			Specificities of Monoclo ", Proc. Natl. Acad. Sci. (				Protein
		Teite	lbaur	n, et	al.,	, "Syn	the	tic Copolyme	er 1 Inhibits Human T-cel				otein",
<u> </u>		Proc Taite	. Nati	n et	ad.	SCI. (	US.	<u>A), 1992, 89,</u>	ameters in a Multicenter C	linical Tris	l of COPL in M	ultiple So	lerosis
		(MS	): A 2	-yea	r Fo	ollow-	-up'	', Neurol., 19	994, <u>44(Suppl. 2)</u> , A358				
		Indu	ced b	y Pro	otec	olipid	Pro	mer 1 Inhibi otein (PLP) P 209-217	ts Chronic Relapsing Expeptides in Mice and Interf	erimental A feres with P	Allergic Encepha LP-specific T C	alomyeliti Cell Respo	s onses", <u>J</u>
									he Laboratory to FDA", I	srael J. Me	d. Sci., 1997, <u>33</u>	3, 280-28	4
EXAMINE	R					<del></del>		CONSIDERI	- <del></del> -		•		
									n is in conformance with MPE xt communication to applicant		line through citatio	n if not in	
			, J. J.										

Page 15 of 16

										uge 15 01					
Form PTO-1	449					nt of Comme ademark Offi		Atty. Doc 60807-AA JPW/ GJO	A-PCT-US/	Serial No. Not Yet Known					
	INFO	ORM.	ATI	ON DI	TATION	Applicants: Alexander Gad and Dora Lis									
(Use several sheets if necessary)								Filing Date Herewith	Group Art Unit						
						U.S. PAT	TENT DOCUMENTS								
Examiner Initial	Docu	ment	Nui	mber		Date	Name	Class	Subclass	Filing Date if Appropriate					
	+		$\vdash$		+			<del></del>							
<u> </u>		1.	<u> </u>			EODEICN I	A TENT DOCUMENT		l						
					_	1	PATENT DOCUMENT		G 1 1	Transl	ation				
	Document Numb					Date	Country	Class	Subclass	Yes No					
			Т	ПТ	1	<del> </del>		<del>                                     </del>		1	1.10				
		-	$\vdash$						<del>                                     </del>	<del> </del>	<del> </del>				
L. L.											<u> </u>				
							ng Author, Title, Date								
	Thon 141	npson	, "M	CQ Tu	tor:	Medical Imm	unology Multiple Choice	e Questions'	', <u>Immunol. Tod</u>	<u>ay,</u> 1985,	<u>6</u> (4),				
							herapy: Is it a Real Poss U.S.A., 1994, <u>91</u> , 437-4		mbat T-Cell-Me	diated					
	I-A <sub>,</sub> d (Absi	loes n tract)	ot in	fluenc	e the	restriction of	ion of the T cell repertoing f hapten-specific T cells	", <u>Eur. J. Im</u>	munol., 1985, 1	5(12): 12					
						"Induction of , 15-20	Long-Term Survival of	Hamster He	art Xenografts i	n Rats",					
	Van Noort, et al., International Review of Cytology, 1996, 178: 127-205														
	Copo	lyme	r", <u>Is</u>	srael J.	Med	<u>l. Sci.,</u> 1972, <u>8</u>	ppression of Experimen 3, 656-657								
	24, 1	13	-				Treatment of Multiple S				•				
	Neur	osurg	ery,	1992,	5, 20	3-211	nd Treatment of Multiple								
	Syntl	hetic I	Basic	In Vivo c Polyp 3, <u>3</u> , 27	epti	des Capable o	nunological Cross-reaction of Suppressing Experime	ons between ental Allergio	Basic Encephal Encephalomye	itogen an litis", <u>Eur</u>	1 <u>. J.</u>				
	Web Basic	b, et a	ıl., "i olyn	Suppre ner", <u>Is</u>	ssioi r. J.	n of Experime Med. Sci., 19	ntal Allergic Encephalo 75, <u>11</u> , 1388 (Abstract)								
	Amir	io Ac	ids".	Immu	noch	nem., 1976, 13	Involved in Suppression 3, 333-337								
		ster's , page			ersi	de University	Dictionary, definition of	f "preventing	", The Riversid	e Publish	ing Co.,				
EXAMINER				DA	ATE	CONSIDERI	E <b>D</b>								
*EXAMINER conformance ar	: Initial if o	citation sidered	cons	sidered, ude cop	wheth	ner or not citation	n is in conformance with MP xt communication to applica	EP 609: Draw nt.	line through citation	on if not in					

Page 16 of 16

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)    Document Number   Date   Name   Class   Subclass   Filing Date   If Appropriate														
(Use several sheets if necessary)    Papeling Date   Pilling Date	Form PTO-1			Pate	ent a	and Ti	rademark Offi	ce	60807-A	A-PCT-US/	Serial No. Not Yet Known			
U.S. PATENT DOCUMENTS    Document Number   Date   Name   Class   Subclass   Filing Date   If Appropriate		. IN					Applicants: Alexander Gad and Dora Lis							
Document Number   Date   Name   Class   Subclass   Filing Date if Appropriate	(Use several sneets if necessary)								Filing Date Group Art			rt Unit		
FOREIGN PATENT DOCUMENTS    Document Number   Date   Country   Class   Subclass   Translation   Yes   No							U.S. PAT	ENT DOCUMENTS						
Document Number   Date   Country   Class   Subclass   Translation   Yes   No	Examiner Initial	Do	cume	nt Nu	mbe	er	Date	Name	Class	Subclass	Filing Date if Appropriate			
Document Number   Date   Country   Class   Subclass   Translation   Yes   No		_	$\vdash$				+							
Document Number   Date   Country   Class   Subclass   Translation   Yes   No	1.			L	ــــــــــــــــــــــــــــــــــــــ	1	FORFICNE	ATENT DACIMENT	I 	<del></del> _				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444  Zisman et al., "Directotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-AL", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED		De	cum-	nt Ni	mba	or				Subclass	Transl	ation		
Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444  Zisman et al., "Dichotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-AL", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		ەط	Cume	.14 14 U		-1	Date		Class		Yes	No		
Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444  Zisman et al., "Dichotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-AL", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in				$\top$										
Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444  Zisman et al., "Dichotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-AL", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in				$\top$		$\sqcap$								
Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444  Zisman et al., "Dichotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-AL", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	I		 	HED	DO:	CIDA	ENTS (Includ:	ng Author Title Date	Pertinent l	Pages Etc.)		<u>.                                    </u>		
Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Wi	ner, "	COP I	Th	erapy	for Multiple Sc	lerosis", New Eng. J. M	<u>led.</u> , 1987, <u>3</u>	<u>17</u> (7), 442-444				
Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)  Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Comple molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	-	7:	Zisman et al. "Dichotomy between the T and the B cellenitones of the synthetic polynentide (T G)-AI."											
molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		Eu	Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)											
EXAMINER DATE CONSIDERED  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		mo	lecule	s on	Anti	igen-P	resenting Cells	and stimulation of a	specific T-ce	ell line require	patibility ( processin	Comple g of th		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in														
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		+												
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in							•							
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in														
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in														
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in												_		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		$\bot$				_								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		-		-										
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	·											0		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	EXAMINER					DATE CONSIDERED								
controller and not actualization missions och) of mis form with many actualization to abbusine.	*EXAMINER conformance ar	: Initial	if citati onsider	on cons	sider ude (	ed, whe	ther or not citation	n is in conformance with MP ext communication to applica	PEP 609: Draw nt.	line through citation	on if not in			